KMG Fiduciary Partners LLC Has $2.49 Million Stock Position in Novo Nordisk A/S $NVO

KMG Fiduciary Partners LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 30.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,957 shares of the company’s stock after selling 22,776 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Novo Nordisk A/S were worth $2,491,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after purchasing an additional 969,916 shares during the period. Franklin Resources Inc. raised its stake in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares during the period. Morgan Stanley grew its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after buying an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S during the 1st quarter worth approximately $287,660,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Analysts set a price target of $65.56 for Novo Nordisk, implying substantial potential upside from the stock’s recent trading level near $47.59. The target supports investor confidence despite recent concerns about the company’s growth outlook. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Positive Sentiment: Novo Nordisk named Amazon Web Services its preferred global cloud and strategic artificial-intelligence partner. A new London innovation hub and AWS tools for drug targeting, therapy design, and clinical-data analysis could help shorten development timelines; more than 25,000 Novo employees have already used the partnership’s tools. Novo Nordisk and Amazon Web Services Collaborate to Advance Drug Discovery
• Positive Sentiment: Hims & Hers’ restructuring and move away from compounded GLP-1 medicines could reduce competition for Novo Nordisk’s approved branded obesity treatments. The development also highlights the regulatory and commercial advantages of established GLP-1 manufacturers. Hims Stock Falls on Earnings
• Neutral Sentiment: Novo Nordisk is supplying semaglutide for Veru’s fully enrolled Phase 2b PLATEAU trial. The combination study could broaden semaglutide’s future applications, but interim results are not expected until the first quarter of 2027. Veru Reports Fiscal 2026 Third Quarter Results and PLATEAU Trial Progress
• Negative Sentiment: Eli Lilly remains Novo Nordisk’s primary rival, with manufacturing capacity increasingly viewed as a competitive moat in the obesity-drug market. The comparison reinforces concerns that market share will depend not only on clinical results but also on each company’s ability to scale supply efficiently. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

Novo Nordisk A/S Trading Up 0.7%

Shares of Novo Nordisk A/S stock opened at $47.59 on Tuesday. The business has a fifty day simple moving average of $47.07 and a two-hundred day simple moving average of $44.81. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market capitalization of $212.49 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 4.31 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be issued a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is currently 42.79%.

Analyst Ratings Changes

NVO has been the subject of several recent research reports. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. BMO Capital Markets restated a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $65.81.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.